Nitrogen-containing bisphosphonates (NBPs) 
potential [2, 9] . ZA has also indirect antitumour effects via its anti-angiogenic [7, 10, 11] and immunomodulatory properties [6, 8, 12, 13] . In view of its high affinity for mineralized bone, in vivo tumour models have mostly addressed the ability of ZA to reduce the skeletal tumour burden or bone metastasis. Few studies have investigated the activity of ZA against tumours not located in bone. In these studies ZA was used at doses exceeding those recommended in the clinical practice [9] [10] [11] [14] [15] [16] . Clinically compatible doses have been used in a mouse model xenografted with human breast cancer cells [17] [18] . These mice develop metastatic tumours with a stepwise progression very similar to that of human breast cancer [19] . [20] were generated by crossing BALB-neuT mice with BALB/c mice KO for IFN-␥ gene from The Jackson Laboratory (Bar Harbor, ME, USA). [24] . To detect the intracellular isopentenyl pyrophosphate (IPP) cells were lysed in ice-cold acetonitrile containing 100 mM NaVO4 as reported [3] , and resolved by thin layer chromatography. 
To gain further insight into the mechanisms underlying any antitumour activity, we have also investigated whether ZA at clinically achievable concentrations can modulate the Mev pathway and protein prenylation in tumour cells and macrophages.

Materials and methods
Mice
BALB-neuT female mice were bred for us under specific pathogen-free conditions by Charles River (Calco, Italy) and treated according to the guidelines established in Principles of Laboratory Animal care (directive 86/609/EEC). Mice were randomly assigned to the control and treated groups, both investigated concurrently. Mammary pads were inspected weekly to monitor the appearance of palpable tumour masses. Masses with a mean diameter of Ն1 mm were regarded as tumours. Growth was monitored until all 10 mammary glands displayed a tumour or until a tumour exceeded a mean diameter of 10 mm, at which time mice were killed for humane reasons. The percentage of mice without tumour in function of time in weeks was evaluated to assess tumour-free survival. Tumour multiplicity was calculated as the cumulative number of incident tumours per total number of mice and is reported as the mean Ϯ S.E.M. To assess tumour growth rate the diameter of each growing tumour was evaluated once a week and reported as the mean tumour diameter Ϯ S.E.M. The percentage of mice alive in function of time in weeks was evaluated to assess overall survival. BALB-neuT mice knocked out (KO) for the interferon-␥ (IFN-␥) gene (BALB-neuT/IFN-␥ KO)
ZA administration
Starting at 7 weeks of age, BALB-neuT mice received repeated courses of saline (control mice) or 100 g/kg of ZA (Novartis Farma, Origgio, Italy) injected intravenously (i.v.) once a week for 4 weeks. This course was repeated after 3 weeks of rest throughout their life.
Morphological analysis and whole mount preparation
Ras prenylation and Ras activity assays
A band shift assay was used to evaluate Ras prenylation [25] 
Electrophoretic mobility shift assay (EMSA)
The activation of nuclear factor (NF)-B was measured in the nuclear extracts of control peritoneal macrophages and ex vivo or in vivo ZA-treated peritoneal macrophages, as previously described [27] . Mouse N11 glial cells incubated for 24 hrs with 20 g/ml LPS were used as positive controls.
Nitrite production
Nitrite production was measured in the supernatant from control peritoneal macrophages and ex vivo or in vivo ZA-treated peritoneal macrophages as previously described [28] and was expressed in nmol nitrite/mg cell proteins. (Fig. 1F) .
Statistical analyses
ZA efficacy in hampering spontaneous lung metastasis was also evaluated [29] . Thirty-week-old ZA-treated mice displayed a significant reduction in the size of metastatic areas as compared to control mice (Fig. S1) .
No evidence of tissue toxicity was detected by histological examination in kidney or other tissues (Fig. S2) , whereas an increase of bone density by CT scanning was detected in ZAtreated mice (Fig. S3 ). (Fig. 3A) . This recruitment was paralleled by intense angiogenesis around mammary ducts displaying tumoral lesions (Fig. 3C) . By contrast, both the number of infiltrating CD11b ϩ macrophages (Fig. 3B) and that of blood vessels associated with the mammary lesions (Fig. 3D) were strongly reduced in ZA-treated mice.
Low-dose ZA inhibits the Mev pathway of TUBO cells
Immunohistochemical analysis showed that both tumourassociated macrophages (TAMs) and tumour cells stained positively for intracytoplasmic VEGF in control mice (Fig. 3E) (Fig. 3F) . The reduced production of VEGF at the tumour site in ZA-treated mice was paralleled by a significant decrease in the serum level of VEGF (Fig. S4) . Fig. 4A) but not IFN-␥ (Fig. 4C) , whereas TAMs of ZA-treated mice stained negative for IL-10 ( Fig. 4B) , and became strongly positive for IFN-␥ (Fig. 4D) . (Fig. 4E) and the same tumour multiplicity (Fig. 4F) [32, 33] . iNOS is negatively regulated by the Mev pathway [34] and positively regulated by NF-B [32, 35] (Fig. 5A) .
ZA-treated mice by a strong reduction of TAMs and tumour cells positively stained for VEGF
Repolarization of TAMs
The weight of this IFN-␥ induction was functionally assessed in BALB-neuT/IFN-␥ KO mice. These mice showed the same tumour-free survival
as their control littermates despite ZA treatment, endorsing the role of IFN-␥ in the ZA-induced impairment of tumour progression.
Fig. 4 ZA's antitumour effect is associated with its ability to reverse TAM polarization from M2 to M1, and is dependent on IFN-␥. Immunohistochemical analysis of representative mammary glands of 18-week-old control (A, C) versus ZAtreated (B, D) BALB-neuT mice. (A, B) Anti IL-10 staining (green) showed a clear reduction of IL-10 release in the tumour microenvironment of ZAtreated mammary tumours. (C, D) A significant enhancement of IFN-␥ release (green) is observed in the microenvironment of ZAtreated mammary tumours. Scale bars, 40 m. (E, F) ZA antitumour activity in BALB-neuT/IFN-␥ KO. BALB-neuT/IFN-␥ KO female mice received weekly i.v. courses of ZA (black line, n ϭ 6) or saline (dotted grey line, n ϭ 7). ZAtreated BALB-neuT/IFN-␥ KO mice displayed the same tumour incidence (E) and tumour multiplicity (F) as control mice.
Expression of iNOS is considered a hallmark of M1 polarized macrophages
. We thus evaluated ZA's ability to inhibit the Mev pathway and induce NF-B-mediated iNOS expression in ex vivo and in vivo ZA-treated peritoneal macrophages. A significant reduction in the amount of FPP, ubiquinone and cholesterol, and a significant increase in the intracellular concentration of IPP was observed in both sets of macrophages, a confirmatory evidence of ZA's ability to specifically inhibit the FPP synthase
Western blot analysis showed that Ras prenylation and Ras-GTP levels were greatly decreased in both ex vivo and in vivo ZAtreated macrophages (Fig. 5B) . These changes were paralleled by a marked reduction in the expression of the inhibitory molecule IB (Fig. 5C) , and an increased translocation of NF-B to the nucleus (Fig. 5D) . Nuclear translocation of NF-B is known to regulate iNOS expression [33, 35] . Macrophages freshly isolated from control mice did not express iNOS (Fig. 5E) , and hence did not produce a significant amount of nitrites, which are stable derivatives of nitric oxide produced by iNOS (Fig. 5F) . By contrast, a strong induction of iNOS expression and a significant increase in the secretion of nitrites were displayed by ex vivo and in vivo ZAtreated macrophages (Fig. 5E and F) . [36] . Nitrotyrosine residues were detected by immunohistochemical staining in the tumour stroma of ZA-treated mice, whereas they were undetectable in control mice (Fig. 5G) [8, 9, 17] . Notably, these results were observed only when ZA administration was started early during the ErbB-2 driven mammary carcinogenesis. ZA becomes ineffective if started when in situ carcinomas had progressed and the angiogenic switch that accompanies the progression to invasive cancer has already taken place (data not shown) [11] .
Nitration of tyrosine residues in tissue proteins is considered an in vivo marker of iNOS induction and local nitric oxide production
It is very unlikely that ZA had a direct effect on tumour cell survival and proliferation in vivo, since the growth rate of TUBO cells, a cloned line derived from a mammary tumour of a BALBneuT mouse [22] , was affected in vitro after 5 days exposure to ZA concentrations from 10 to 100 times higher than those achievable in vivo. Indeed, most reports have shown that ZA has a direct antitumour activity in vitro at concentrations ranging from 50 M to 1 mM, whereas lower concentrations are conceded if ZA is given in combination with standard anti-neoplastic agents [38, 39] , or molecularly targeted agents, such as imatinib and tipifarnib [15, 40, 41] .
Although labelled as in (C). (E, F) [10, 11, 14] .
Induction of iNOS expression and nitrite production. (E) Western blot analysis of iNOS and GAPDH in protein lysates from cell preparations run in lanes labelled as in (C and D). Results shown in (B-E) are from one representative out of three experiments. (F) Nitrite secretion by CTRL, ZA 24 hrs and ZA macrophages (MAC). Untreated (N11 CTRL) or LPS-treated (N11 LPS) N11 glial cells were used as controls. Results are expressed as mean Ϯ S.E.M. of three experiments. The difference between ZA 24 hrs and CTRL macrophages is statistically significant (*P Ͻ 0.01, Student's t-test). (G) Nitrotyrosine expression (arrowheads) in the tumour
The clinically compatible doses of ZA used in our study add further weight to the role of TAMs as critical targets bridging ZAmediated antitumour and anti-angiogenic activity. Given their high endocytic activity, similar to that of osteoclasts with whom they share the same ontogeny, TAMs are in a privileged position to internalize ZA, even at the low concentrations they were exposed to in BALB-neuT mice. Indeed, we have previously shown that ZA at concentrations ranging from 0.5 to 1 M deeply modulate the Mev pathway of monocytes and monocyte-derived dendritic cells [6] .
Views about the role of TAMs in the tumour microenvironment have changed when they were found to display a polarized M2 phenotype and to sustain tumour growth and metastasis by reprogramming the local microenvironment and host immunity in favour of tumour cells [31] [32] [33] [31, 32] , and this presumption was formally proved by the lack of efficacy of ZA treatment in IFN-␥ KO transgenic mice. [31, 35] . iNOS is considered a hallmark of M1 macrophages [33] and its expression is inhibited by GTPase signalling proteins [34] [44] . IPP is a phosphoantigen that stimulates the unique subset of V␥9/V␦2 T cells [45] . The antitumour potential of ZA in human beings has also been ascribed to stimulation of V␥9/V␦2 T cells via the accumulation of IPP in tumour cells [13] and antigen-presenting cells, such as monocytes and dendritic cells [6] [46] , NKT stimulation with the glycolipid ␣GalCer [47] , tumour-specific vaccination [11, 20] 
LPS and IFN-␥ induce iNOS expression in macrophages by activating the NF-B and STAT signalling pathways
